Tygh Capital Management’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | $10.9M | Buy |
181,055
+26,614
| +17% | +$1.6M | 1.39% | 29 |
|
|
2021
Q3 | $8.65M | Buy |
154,441
+2,109
| +1% | +$118K | 1.17% | 40 |
|
|
2021
Q2 | $9.24M | Buy |
152,332
+57,725
| +61% | +$3.5M | 1.26% | 34 |
|
|
2021
Q1 | $6.63M | Sell |
94,607
-72,610
| -43% | -$5.09M | 0.94% | 47 |
|
|
2020
Q4 | $10M | Buy |
167,217
+27,882
| +20% | +$1.67M | 1.56% | 22 |
|
|
2020
Q3 | $8.38M | Buy |
139,335
+62,160
| +81% | +$3.74M | 1.59% | 22 |
|
|
2020
Q2 | $4.05M | Buy |
+77,175
| New | +$4.05M | 0.84% | 52 |
|
|
2019
Q1 | – | Sell |
-88,501
| Closed | -$3.81M | – | 87 |
|
|
2018
Q4 | $3.81M | Buy |
+88,501
| New | +$3.81M | 0.8% | 59 |
|
|
2018
Q1 | – | Sell |
-91,161
| Closed | -$4.16M | – | 102 |
|
|
2017
Q4 | $4.16M | Buy |
+91,161
| New | +$4.16M | 0.78% | 61 |
|
|
2017
Q3 | – | Sell |
-58,710
| Closed | -$2.8M | – | 96 |
|
|
2017
Q2 | $2.8M | Sell |
58,710
-51,410
| -47% | -$2.45M | 0.63% | 76 |
|
|
2017
Q1 | $5.02M | Buy |
+110,120
| New | +$5.02M | 1.17% | 39 |
|
|
2016
Q2 | – | Sell |
-32,795
| Closed | -$1.74M | – | 94 |
|
|
2016
Q1 | $1.74M | Sell |
32,795
-43,844
| -57% | -$2.32M | 0.51% | 80 |
|
|
2015
Q4 | $5.89M | Buy |
+76,639
| New | +$5.89M | 1.65% | 16 |
|
|
2015
Q3 | – | Sell |
-36,987
| Closed | -$2.62M | – | 104 |
|
|
2015
Q2 | $2.62M | Sell |
36,987
-33,821
| -48% | -$2.39M | 0.47% | 85 |
|
|
2015
Q1 | $6.29M | Buy |
70,808
+13,381
| +23% | +$1.19M | 1.16% | 31 |
|
|
2014
Q4 | $5.09M | Buy |
57,427
+44,356
| +339% | +$3.93M | 0.99% | 46 |
|
|
2014
Q3 | $1.27M | Buy |
+13,071
| New | +$1.27M | 0.28% | 97 |
|
|
2013
Q4 | – | Sell |
-125,118
| Closed | -$6.02M | – | 128 |
|
|
2013
Q3 | $6.02M | Sell |
125,118
-134,994
| -52% | -$6.49M | 1.35% | 23 |
|
|
2013
Q2 | $7.54M | Buy |
+260,112
| New | +$7.54M | 1.67% | 11 |
|